| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURHEARTJ/EHQ255 |
| P698 | PubMed publication ID | 20685681 |
| P50 | author | Franz H. Messerli | Q106567879 |
| Faiez Zannad | Q19631268 | ||
| Jan A. Staessen | Q37390604 | ||
| P2860 | cites work | Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study). | Q44210754 |
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| The LIFE study: the straw that should break the camel's back | Q44366508 | ||
| Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study | Q44601096 | ||
| Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure | Q44604921 | ||
| Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension | Q44842269 | ||
| Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials | Q45113230 | ||
| Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators | Q45165979 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats | Q47298474 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology | Q55050673 | ||
| Dual inhibition of the renin system by aliskiren and valsartan | Q57085467 | ||
| 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 | ||
| Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis | Q24646726 | ||
| Oral renin inhibitors | Q28269879 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure | Q28748219 | ||
| Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. | Q33674294 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| Renal and retinal effects of enalapril and losartan in type 1 diabetes | Q34296719 | ||
| Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. | Q34369863 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study | Q34586729 | ||
| Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi | Q37125268 | ||
| Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. | Q37344514 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Asse | Q43273403 | ||
| P433 | issue | 18 | |
| P304 | page(s) | 2205-2208 | |
| P577 | publication date | 2010-08-03 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Of fads, fashion, surrogate endpoints and dual RAS blockade | |
| P478 | volume | 31 |
| Q41608603 | Anti-fibrotic Potential of AT2 Receptor Agonists |
| Q90400249 | Comparison of Renal Effects of Ezetimibe-Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
| Q36701736 | Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease |
| Q37053287 | Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence? |
| Q36567554 | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials |
| Q37982211 | Evaluation and pharmacologic approach to patients with resistant hypertension |
| Q57312402 | Intensive glucose control improves kidney outcomes in patients with type 2 diabetes |
| Q38076689 | Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed |
| Q47556312 | Left ventricular hypertrophy and cognitive function: a systematic review |
| Q45741432 | Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus |
| Q36648115 | Reduction of mean arterial pressure and proteinuria by the effect of ACEIs (Lisinopril) in Kurdish hypertensive patients in Hawler City |
| Q38208867 | Resistant hypertension: current status, future challenges |
| Q37891794 | Stroke, high blood pressure and the Renin-Angiotensin-aldosterone system - new developments |
| Q34122611 | The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis |
| Q37997869 | The efficacy of renal angioplasty in patients with renal artery stenosis and flash oedema or congestive heart failure: a systematic review |
| Q28543430 | The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders |
Search more.